comprehensive -WSS

comprehensive

author：explore 2025-09-27 12:48:16 - browse：1363

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Watch the official trailer for 'Ahsoka' series

explore

WSS

Women's World Cup brings attention to abuse in soccer

CDC recommends rationing of RSV shot due to shortages

CDC recommends rationing of RSV shot due to shortages

Physician subsidies by hospitals soar in wake of No Surprises Act

Emergency medicine has repudiated 'excited delirium.' Now what?

First Opinion Podcast: How to protect health care in times of war

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Medical records are filled with copy

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

Psychedelics group wrestles with new pharma identity

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Britney Spears to release memoir, 'The Woman In Me,' later this year

Medicare proposal to cover medical devices draws a mixed reaction

How are insurers handling Leqembi and related scans?

At least 13 dead in Texas as scorching temps continue

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

hotspot

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

Readout Newsletter: New research from Sanofi, Regeneron, etc.

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Eli Lilly to pay $200M for Beam’s stake in gene

Wikipedia

hotspot

explore

focus